Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25561511)

  • 1. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
    Kopetz S; Tabernero J; Rosenberg R; Jiang ZQ; Moreno V; Bachleitner-Hofmann T; Lanza G; Stork-Sloots L; Maru D; Simon I; Capellà G; Salazar R
    Oncologist; 2015 Feb; 20(2):127-33. PubMed ID: 25561511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
    Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
    Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 4. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
    Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
    Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers.
    Fu T; Pappou EP; Guzzetta AA; Calmon Mde F; Sun L; Herrera A; Li F; Wolfgang CL; Baylin SB; Iacobuzio-Donahue CA; Tong W; Ahuja N
    Ann Surg; 2016 Feb; 263(2):337-44. PubMed ID: 25822686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
    Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
    Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
    Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
    Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
    Woodard GA; Gubens MA; Jahan TM; Jones KD; Kukreja J; Theodore PR; Cardozo S; Jew G; Clary-Macy C; Jablons DM; Mann MJ
    Clin Lung Cancer; 2014 Nov; 15(6):426-32. PubMed ID: 25258195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells.
    Lloyd JM; McIver CM; Stephenson SA; Hewett PJ; Rieger N; Hardingham JE
    Clin Cancer Res; 2006 Jan; 12(2):417-23. PubMed ID: 16428481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
    Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
    Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors.
    Kang SI; Kim DW; Kwak Y; Lee HS; Kim MH; Kim MJ; Oh HK; Kang SB
    Int J Colorectal Dis; 2018 Jun; 33(6):719-726. PubMed ID: 29594445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
    Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
    J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients.
    Sveen A; Ågesen TH; Nesbakken A; Meling GI; Rognum TO; Liestøl K; Skotheim RI; Lothe RA
    Clin Cancer Res; 2012 Nov; 18(21):6001-10. PubMed ID: 22991413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.